The milestone approval for Amgen’s drug Lumakras will galvanize targeted therapy efforts against Ras oncoproteins and provides a powerful new last line of defense for patients with lung cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
12 October 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-01120-1
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Oncologists greet Lumakras: the world’s first KRAS inhibitor. Nat Biotechnol 39, 1032–1034 (2021). https://doi.org/10.1038/s41587-021-01053-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01053-9
